Science News
from research organizations

Non-hormonal management of menopausal vasomotor symptoms

Date:
May 7, 2015
Source:
Elsevier
Summary:
Hot flashes are a common menopausal symptom. They tend to intensify during the perimenopause and usually subside within 5 years after the final menstrual period. However in some women frequent hot flashes are a long term problem and may last for more than 7 years. While estrogen-based menopausal hormone therapy is the most effective treatment it is not indicated for all women, such as those with a personal history of breast cancer. A new position statement provides a practical guide to non-hormonal management.
Share:
FULL STORY

Elsevier journal Maturitas today announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) covering non-hormonal management of menopausal vasomotor symptoms.

Hot flashes are a common menopausal symptom. They tend to intensify during the perimenopause and usually subside within 5 years after the final menstrual period. However in some women frequent hot flashes are a long term problem and may last for more than 7 years. While estrogen-based menopausal hormone therapy is the most effective treatment it is not indicated for all women, such as those with a personal history of breast cancer. The position statement provides a practical guide to non-hormonal management.

It covers lifestyle modifications, diet and food supplements, non-hormonal medications and use of behavioral and alternative medicine therapies. The key conclusions are that there is insufficient or conflicting evidence to suggest that exercise, supplements or a diet rich in phytoestrogens are effective for hot flashes. Selective serotonin-reuptake inhibitors (SSRIs), serotonin norepinephrine-reuptake inhibitors (SNRIs) and gabapentin could be proposed as alternatives to estrogen-based therapies. Behavioral therapies and alternative medicine interventions have been tried, but the available evidence is still limited.

Thus women who cannot take estrogens should be able to discuss non-hormonal options with their health professional.

These and other recommendations presented in EMAS' position statement are published in the article: "EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms" in Maturitas published by Elsevier:


Story Source:

Materials provided by Elsevier. Note: Content may be edited for style and length.


Journal Reference:

  1. Gesthimani Mintziori, Irene Lambrinoudaki, Dimitrios G. Goulis, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Faustino R. Pérez-López, Karin Schenck-Gustafsson, Tommaso Simoncini, Florence Tremollieres, Margaret Rees. EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. Maturitas, 2015; DOI: 10.1016/j.maturitas.2015.04.009

Cite This Page:

Elsevier. "Non-hormonal management of menopausal vasomotor symptoms." ScienceDaily. ScienceDaily, 7 May 2015. <www.sciencedaily.com/releases/2015/05/150507082529.htm>.
Elsevier. (2015, May 7). Non-hormonal management of menopausal vasomotor symptoms. ScienceDaily. Retrieved May 26, 2017 from www.sciencedaily.com/releases/2015/05/150507082529.htm
Elsevier. "Non-hormonal management of menopausal vasomotor symptoms." ScienceDaily. www.sciencedaily.com/releases/2015/05/150507082529.htm (accessed May 26, 2017).

RELATED STORIES